揭示呋塞米在脓毒症中的未开发潜力:真实世界证据关于凝血病和器官结局
该研究利用台湾全民健康保险研究数据库(2000-2013年)构建了9,934例成人新发脓毒症的匹配队列,比较住院期间使用呋塞米与其他利尿剂(如乙酰唑胺、氢氯噻嗪、螺内酯)的结局。主要结局为弥散性血管内凝血,次要结局包括输血、器官衰竭(心、呼吸、肾、肝)和全因死亡。3个月随访时,呋塞米使用与弥散性血管内凝血风险降低相关(校正风险比0.196,95%CI 0.067-0.516,P<0.001),并与输血减少相关;12个月探索性分析中关联持续。心脏、呼吸和急性肾衰竭也观察到显著保护关联,全因死亡率更低。主动对照分析显示死亡关联为利尿剂类共享,而器官衰竭保护关联为呋塞米特有,作者认为这提示超越一般利尿作用的独特药理效应,并生成与Na+-K+-2Cl-协同转运蛋白1相关抗氧化和抗炎通路一致的生物学假说,需前瞻性试验确认。
要点
- 在9,934例成人新发脓毒症匹配队列中,住院期间使用呋塞米与3个月随访时弥散性血管内凝血风险降低相关(校正风险比0.196,95%CI 0.067-0.516,P<0.001)。
- 呋塞米使用还与输血减少相关,且在12个月探索性分析中这些关联持续存在。
- 心脏、呼吸和急性肾衰竭也观察到显著保护关联,全因死亡率更低。
- 主动对照分析显示,死亡关联为各利尿剂类共享,而器官衰竭保护关联为呋塞米特有,未在其他利尿剂中观察到。
- 作者认为这些发现生成与Na+-K+-2Cl-协同转运蛋白1相关抗氧化和抗炎通路一致的生物学假说,需前瞻性试验确认。
适用人群与场景
- 台湾全民健康保险研究数据库(2000-2013年)中9,934例成人新发脓毒症患者,住院期间接受呋塞米者与接受其他利尿剂(如乙酰唑胺、氢氯噻嗪、螺内酯)者比较。
研究设计与关键结果
- 研究类型:基于台湾全民健康保险研究数据库(2000-2013年)的人群匹配队列,样本量9,934例成人新发脓毒症。
- 主要结局:3个月随访时,呋塞米使用与弥散性血管内凝血风险降低相关(校正风险比0.196,95%CI 0.067-0.516,P<0.001),并与输血减少相关;12个月探索性分析中关联持续。
- 次要结局:心脏、呼吸和急性肾衰竭观察到显著保护关联,全因死亡率更低。
- 主动对照分析:死亡关联为各利尿剂类共享,器官衰竭保护关联为呋塞米特有,未在其他利尿剂中观察到。
证据类型、等级与局限
- 证据类型:基于台湾全民健康保险研究数据库(2000-2013年)的真实世界人群匹配队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,真实世界证据提示呋塞米使用与脓毒症相关凝血病减少和有利器官结局相关,这些发现生成生物学假说,需前瞻性试验确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis-related coagulopathy is a major driver of organ failure and mortality, yet effective adjuncts remain limited. We therefore examined whether early furosemide use is associated with reduced coagulopathy and improved organ outcomes in real-world practice.
METHODS: Using Taiwan's National Health Insurance Research Database (2000-2013), we assembled a population-based matched cohort of 9,934 adults with incident sepsis. Exposure was receipt of furosemide during the index hospitalization; comparators were other diuretics (e.g., acetazolamide, hydrochlorothiazide, and spironolactone). The primary outcome was disseminated intravascular coagulation; secondary outcomes included transfusion, organ failures (cardiac, respiratory, renal, and hepatic), and all-cause mortality. Multivariable Cox models estimated adjusted hazard ratios.
RESULTS: In the primary analysis (3-month follow-up), furosemide use was associated with a lower risk of disseminated intravascular coagulation (adjusted hazard ratio 0.196, 95% confidence interval 0.067-0.516, P < 0.001) and transfusion. These associations remained durable in the exploratory 12-month analysis. Significant protective associations were also observed for cardiac, respiratory, and acute renal failure, alongside lower all-cause mortality. Crucially, active comparator analysis revealed that while associations with lower mortality were shared across diuretic classes, the protective associations with organ failure were specific to furosemide and not observed with other diuretics, supporting a distinct pharmacological effect beyond general diuresis.
CONCLUSIONS: Real-world evidence suggests that furosemide use is associated with reduced sepsis-related coagulopathy and favorable organ outcomes. These findings generate a biologically plausible hypothesis consistent with Na + -K + -2Cl - cotransporter 1-related antioxidant and anti-inflammatory pathways observed in preclinical models, warranting confirmation in prospective trials.
参考来源
- Hung HY, Chung CH, Shih CC, et al. Uncovering the Untapped Potential of Furosemide in Sepsis: Real-World Evidence on Coagulopathy and Organ Outcomes. Shock. 2026. PMID: 41773857. doi:10.1097/SHK.0000000000002828
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。